These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24256452)

  • 1. Exploring concepts of in vitro time-dependent CYP inhibition assays.
    Stresser DM; Mao J; Kenny JR; Jones BC; Grime K
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):157-74. PubMed ID: 24256452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
    Li P; Lu C; Balani SK; Gan LS
    Drug Metab Dispos; 2011 Jun; 39(6):1054-7. PubMed ID: 21393461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of stable isotope labeled probes to facilitate liquid chromatography/mass spectrometry based high-throughput screening of time-dependent CYP inhibitors.
    Dasgupta M; Tang W; Caldwell GW; Yan Z
    Rapid Commun Mass Spectrom; 2010 Aug; 24(15):2177-85. PubMed ID: 20583325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach.
    Mukadam S; Tay S; Tran D; Wang L; Delarosa EM; Khojasteh SC; Halladay JS; Kenny JR
    Drug Metab Lett; 2012 Mar; 6(1):43-53. PubMed ID: 22372554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo.
    Zhao P
    Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):151-64. PubMed ID: 18330044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design.
    Perloff ES; Mason AK; Dehal SS; Blanchard AP; Morgan L; Ho T; Dandeneau A; Crocker RM; Chandler CM; Boily N; Crespi CL; Stresser DM
    Xenobiotica; 2009 Feb; 39(2):99-112. PubMed ID: 19255936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
    Takusagawa S; Miyashita A; Iwatsubo T; Usui T
    Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
    McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
    Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs.
    Zimmerlin A; Trunzer M; Faller B
    Drug Metab Dispos; 2011 Jun; 39(6):1039-46. PubMed ID: 21383203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.
    Grimm SW; Einolf HJ; Hall SD; He K; Lim HK; Ling KH; Lu C; Nomeir AA; Seibert E; Skordos KW; Tonn GR; Van Horn R; Wang RW; Wong YN; Yang TJ; Obach RS
    Drug Metab Dispos; 2009 Jul; 37(7):1355-70. PubMed ID: 19359406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput, 384-well, LC-MS/MS CYP inhibition assay using automation, cassette-analysis technique, and streamlined data analysis.
    Halladay JS; Delarosa EM; Tran D; Wang L; Wong S; Khojasteh SC
    Drug Metab Lett; 2011 Aug; 5(3):220-30. PubMed ID: 21867481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of solvents on the time-dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes.
    Aasa J; Hu Y; Eklund G; Lindgren A; Baranczewski P; Malmquist J; Turek D; Bueters T
    Drug Metab Dispos; 2013 Jan; 41(1):159-69. PubMed ID: 23073735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design.
    Di L; Keefer C; Scott DO; Strelevitz TJ; Chang G; Bi YA; Lai Y; Duckworth J; Fenner K; Troutman MD; Obach RS
    Eur J Med Chem; 2012 Nov; 57():441-8. PubMed ID: 22840492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
    Brown HS; Wilby AJ; Alder J; Houston JB
    Drug Metab Dispos; 2010 Dec; 38(12):2139-46. PubMed ID: 20847136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
    Brown HS; Chadwick A; Houston JB
    Drug Metab Dispos; 2007 Nov; 35(11):2119-26. PubMed ID: 17724064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry.
    Qin CZ; Ren X; Tan ZR; Chen Y; Yin JY; Yu J; Qu J; Zhou HH; Liu ZQ
    Biomed Chromatogr; 2014 Feb; 28(2):197-203. PubMed ID: 23946123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
    Kumar G; Lau H; Laskin O
    Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.
    Lee KS; Kim SK
    J Appl Toxicol; 2013 Feb; 33(2):100-8. PubMed ID: 21915887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions.
    Thelingwani RS; Zvada SP; Dolgos H; Ungell AL; Masimirembwa CM
    Drug Metab Dispos; 2009 Jun; 37(6):1286-94. PubMed ID: 19299526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates.
    Cali JJ; Ma D; Wood MG; Meisenheimer PL; Klaubert DH
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1115-30. PubMed ID: 22686499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.